Kuriakose Emil 4

What Happened Kuriakose Emil, Chief Medical Officer of Terns Pharmaceuticals (TERN), sold 942 shares on April 1, 2026, for a total of approximately $49,693. The sale was reported on a Form 4 filed April 2, 2026 and is noted as an open-market/private sale to satisfy tax withholding associated with the vesting of a previously granted restricted stock unit (RSU) award.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-02 (appears timely).
• Shares sold: 942 at a weighted-average price of $52.75 per share (range $52.735–$52.77).
• Proceeds: ~$49,693.
• Transaction code: S (Sale). Footnote F1: sale made to satisfy taxes on RSU vesting (not a discretionary trade). Footnote F2: sale price is a weighted average across the indicated range; detailed split available on request.
• Shares owned after the transaction: not specified in the provided summary—see the full Form 4 for holdings details.

Context Tax-withholding sales following RSU vesting are common and typically procedural (used to cover tax obligations) rather than a direct signal of the insider’s view on the company. This was not an option exercise or a gift; it was a sale tied to tax withholding.